A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia

Abstract

This novel agonist of the erythropoietin receptor can correct anemia in patients with pure red-cell aplasia caused by antierythropoietin antibodies. (ClinicalTrials.gov number, NCT00314795.).